ATE324440T1 - Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzen - Google Patents
Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzenInfo
- Publication number
- ATE324440T1 ATE324440T1 AT99903559T AT99903559T ATE324440T1 AT E324440 T1 ATE324440 T1 AT E324440T1 AT 99903559 T AT99903559 T AT 99903559T AT 99903559 T AT99903559 T AT 99903559T AT E324440 T1 ATE324440 T1 AT E324440T1
- Authority
- AT
- Austria
- Prior art keywords
- antisense oligonucleotides
- dna methyltransferase
- oligonucleotides complementary
- optimized antisense
- methyltransferase sequences
- Prior art date
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 3
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 3
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 3
- 108060004795 Methyltransferase Proteins 0.000 title abstract 2
- 230000000295 complement effect Effects 0.000 title abstract 2
- 102000016397 Methyltransferase Human genes 0.000 title 1
- 238000013459 approach Methods 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940124606 potential therapeutic agent Drugs 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/018,034 US6066625A (en) | 1998-02-03 | 1998-02-03 | Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE324440T1 true ATE324440T1 (de) | 2006-05-15 |
Family
ID=21785911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99903559T ATE324440T1 (de) | 1998-02-03 | 1999-02-03 | Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzen |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6066625A (de) |
| EP (1) | EP1053313B1 (de) |
| JP (1) | JP3766592B2 (de) |
| AT (1) | ATE324440T1 (de) |
| AU (1) | AU758835B2 (de) |
| CA (1) | CA2319086A1 (de) |
| DE (1) | DE69931029T2 (de) |
| DK (1) | DK1053313T3 (de) |
| ES (1) | ES2263267T3 (de) |
| PT (1) | PT1053313E (de) |
| WO (1) | WO1999040186A1 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032610A1 (en) | 1996-06-03 | 2003-02-13 | Gilchrest Barbara A. | Method to inhibit cell growth using oligonucleotides |
| US7026155B2 (en) * | 1999-02-02 | 2006-04-11 | Regents Of The University Of California | Method of reducing bacterial proliferation |
| WO2001085996A1 (en) * | 2000-05-09 | 2001-11-15 | Isis Pharmaceuticals, Inc. | Methods of obtaining active antisense compounds |
| AU2002342417A1 (en) * | 2001-05-11 | 2002-11-25 | Methylgene, Inc. | Inhibitors of dna methyltransferase isoforms |
| EP1851339B1 (de) | 2005-02-11 | 2016-05-18 | Memorial Sloan-Kettering Cancer Center | Verfahren und zusammensetzungen zum nachweis einer arzneistoffresistenten egfr-mutante |
| US20060252723A1 (en) * | 2005-04-01 | 2006-11-09 | Methylgene, Inc. The Cleveland Clinic Foundation | Combined therapy utilizing reduction of DNA methyltransferase expression and/or activity and interferon |
| NZ564283A (en) | 2005-05-20 | 2011-07-29 | Methylgene Inc | Inhibitors of VEGF receptor and HGF receptor signaling |
| CA2617611A1 (en) * | 2005-08-01 | 2007-02-08 | Nupotential, Llc | Production of reprogrammed cells with restored potential |
| RS63964B1 (sr) | 2005-08-23 | 2023-03-31 | Univ Pennsylvania | Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu |
| WO2007107005A1 (en) * | 2006-03-22 | 2007-09-27 | Methylgene, Inc. | Inhibitors of protein tyrosine kinase activity |
| WO2008035209A2 (en) * | 2006-05-30 | 2008-03-27 | Methylgene Inc. | Inhibitors of protein tyrosine kinase activity |
| WO2008046216A1 (en) * | 2006-10-18 | 2008-04-24 | Methylgene, Inc. | Kinase inhibitors and uses thereof |
| WO2009089598A2 (en) * | 2008-01-18 | 2009-07-23 | Katholieke Universiteit Leuven | Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer |
| AU2009303602B2 (en) | 2008-10-14 | 2012-06-14 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
| GB201001088D0 (en) | 2010-01-23 | 2010-03-10 | Trillion Genomics Ltd | Detection |
| MY181439A (en) | 2011-02-28 | 2020-12-22 | Sunshine Lake Pharma Co Ltd | Substituted quinoline compounds and methods of use |
| GB201206209D0 (en) | 2012-04-06 | 2012-05-23 | Univ Leuven Kath | Marker gene based diagnosis, staging and prognosis of prostate caner |
| MX2015001424A (es) | 2012-07-28 | 2016-03-09 | Calitor Sciences Llc | Compuestos pirazolona sustituidos y metodos de uso. |
| TWI574962B (zh) | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途 |
| BR112015018318A2 (pt) | 2013-02-21 | 2017-08-22 | Sunshine Lake Pharma Co Ltd | Composto, composição farmacêutica, uso de um composto ou de uma composição farmacêutica, e, métodos para prevenir, gerenciar, tratar ou diminuir a severidade de um distúrbio proliferativo em um paciente e para inibir ou modular a atividade de uma proteína quinase em uma amostra biológica |
| WO2014160243A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
| EP3124609A1 (de) | 2015-07-29 | 2017-02-01 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | Therapeutische oligonukleotide |
| PL3329004T3 (pl) | 2015-07-29 | 2020-10-05 | Ifom Fondazione Istituto Firc Di Oncologia Molecolare | Terapeutyczne oligonukleotydy |
| AU2016343517B2 (en) | 2015-10-19 | 2020-04-30 | Sunshine Lake Pharma Co., Ltd. | A salt of EGFR inhibitor, crystalline form and uses thereof |
| WO2018185341A1 (en) | 2017-04-07 | 2018-10-11 | Ospedale San Raffaele S.R.L. | Regulator of bmp-smad signaling and uses thereof |
| WO2018194342A2 (en) * | 2017-04-17 | 2018-10-25 | Seegene, Inc. . | Methods for preparing optimal combination of oligonucleotides |
| US20250019700A1 (en) * | 2021-11-08 | 2025-01-16 | The General Hospital Corporation | Treating chemoresistant forms of leukemia and other cancers that overexpress rna binding protein fxr1 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5030557A (en) * | 1987-11-24 | 1991-07-09 | Ml Technology Venture | Means and method for enhancing nucleic acid hybridization |
| US5652355A (en) * | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
| US5578716A (en) * | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
-
1998
- 1998-02-03 US US09/018,034 patent/US6066625A/en not_active Expired - Fee Related
-
1999
- 1999-02-03 EP EP99903559A patent/EP1053313B1/de not_active Expired - Lifetime
- 1999-02-03 WO PCT/CA1999/000092 patent/WO1999040186A1/en not_active Ceased
- 1999-02-03 ES ES99903559T patent/ES2263267T3/es not_active Expired - Lifetime
- 1999-02-03 DE DE69931029T patent/DE69931029T2/de not_active Expired - Fee Related
- 1999-02-03 AU AU24059/99A patent/AU758835B2/en not_active Ceased
- 1999-02-03 DK DK99903559T patent/DK1053313T3/da active
- 1999-02-03 AT AT99903559T patent/ATE324440T1/de not_active IP Right Cessation
- 1999-02-03 CA CA002319086A patent/CA2319086A1/en not_active Abandoned
- 1999-02-03 PT PT99903559T patent/PT1053313E/pt unknown
- 1999-02-03 JP JP2000530600A patent/JP3766592B2/ja not_active Expired - Fee Related
-
2000
- 2000-05-22 US US09/575,506 patent/US6506735B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU758835B2 (en) | 2003-04-03 |
| JP2002502602A (ja) | 2002-01-29 |
| PT1053313E (pt) | 2006-06-30 |
| DE69931029D1 (de) | 2006-06-01 |
| US6506735B1 (en) | 2003-01-14 |
| DE69931029T2 (de) | 2006-11-23 |
| US6066625A (en) | 2000-05-23 |
| JP3766592B2 (ja) | 2006-04-12 |
| EP1053313A1 (de) | 2000-11-22 |
| CA2319086A1 (en) | 1999-08-12 |
| DK1053313T3 (da) | 2006-08-28 |
| ES2263267T3 (es) | 2006-12-01 |
| AU2405999A (en) | 1999-08-23 |
| WO1999040186A1 (en) | 1999-08-12 |
| EP1053313B1 (de) | 2006-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69931029D1 (de) | Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzen | |
| DK0691980T3 (da) | 7-deazapurinmodifiderende oligonukleotider | |
| WO1999010486A3 (en) | Mdm2-specific antisense oligonucleotides | |
| PT731835E (pt) | Oligonucleotidos anti-sentido possuindo actividade inibidora de tumorigenicidade | |
| DE69934227D1 (de) | Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide | |
| DE69838449D1 (de) | Aminooxy-modifizierte oligonukleotide | |
| ATE312202T1 (de) | Menschliche rnase h und entsprechende oligonukleotidverbindungen | |
| IL113804A0 (en) | Antisense oligonucleotide modulation of raf gene expression | |
| DE69433626D1 (de) | N-2 substituierte purine | |
| EP0788307A4 (de) | Oligonukleotidmodulation von multidrogenresistenz-assoziertem protein | |
| WO1998054313A3 (en) | Dna methyltransferase genomic sequences and antisense oligonucleotides | |
| WO2001032832A3 (en) | Antisense inhibition of nucleolin expression | |
| ATE275956T1 (de) | Veränderung der dns methyltransferase durch kombinationstherapie | |
| DK1175489T3 (da) | Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider | |
| WO2000029623A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
| WO1998032846A3 (en) | Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos | |
| ATE465261T1 (de) | Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken | |
| WO2001048245A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
| EP1322658A4 (de) | Oligonukleotidmodulation der her-1-expression | |
| DE69430740D1 (de) | ANTISENSE OLIGONNUKLEOTIDE DIE MIT DER mRNA CAP AKTIVITÄT INTERFERIEREN UND DIE TRANSLATION INHIBIEREN | |
| WO2002091926A3 (en) | Inhibitors of dna methyltransferase isoforms | |
| WO2001051670A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
| WO2000029622A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
| WO2001038586A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
| AU3956100A (en) | Rna polymerase i transcription factor tif-ia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1053313 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |